+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Pregabalin Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997435
  • Report
  • March 2020
  • Region: Global
  • 110 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Cipla Limited
  • Dr. Reddy's Laboratories
  • MSN Laboratories Ltd
  • Mylan
  • Pfizer
  • Teva Pharmaceuticals
  • MORE
The global pregabalin market is projected to grow with a CAGR of nearly 3% over the forecast period. The market is primarily driven by the growing prevalence of epilepsy, neuropathic pain and related disorders globally. In addition, growing geriatric population coupled with the increasing prevalence of diabetes, neuropathic pain, fibromyalgia and others anticipated to fuel the market growth over the forecast period. According to the International Diabetes Federation, 463 million people were diabetic worldwide as of 2019. This number expected to grow to 700 million by 2045.

Moreover, the company’s efforts in broadening the applications of pregabalin through R&D is expected to boost market growth. However, the availability of alternatives, adverse effects and stringent regulatory policies are expected to hamper the market growth.

Key Market Trends

Neuropathic Pain Application Segment Anticipated to Grow at Significant Rates

Neuropathic pain often refers as burning or shooting pain. It is usually caused by the damage of nerves. Pregabalin used to reduce neuropathic pain by blocking the pain signals. The increasing cases of neuropathic pain and growing risk factors such as diabetes and HIV anticipated to fuel the market growth. According to the International Study of Neuropathic Pain (2014-2015), about 7-8% global population are living with chronic pain with neuropathic characters.

In addition, the patent expiry of Pfizer’s Lyrica (pregabalin) in 2019, has increased the market share for generic drug manufacturers in the market. Also, continuous R&D in widening the applications of pregabalin in different disease interventions coupled with recent product launches anticipated to boost the market growth.

Due to the success of Pfizer’s Lyrica, many of the manufacturers has applied for pregabalin production worldwide. Moreover, the increasing number of geriatric population with neurological disorders anticipated to fuel the market growth over the forecast period.

North America Expected to Have Significant Market Growth

Among the regional segment, North America is expected to have significant market growth over the forecast period. This growth is attributed to growing prevalence of chronic diseases, well established healthcare infrastructure and high adoption of advanced technologies and government initiatives to mandate the maintenance of health records.

However, Asia Pacific region is projected to have lucrative market growth opportunities owing to the presence of large pool of patient population, increasing need for better risk management solutions, adoption of recording and maintaining the health records and growing prevalence of chronic diseases.

Competitive Landscape

Global pregabalin market is moderately consolidated with the limited number of market players. However, the market is anticipated to be intense due to recent approvals of generic manufacturers. Market players are focusing on new product launches and geographical expansions to increase the market share. The key market players operating in the market include Pfizer Inc., Mylan N.V., Teva Pharmaceuticals, Cipla Limited, and Medley Pharmaceuticals Limited among others

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Cipla Limited
  • Dr. Reddy's Laboratories
  • MSN Laboratories Ltd
  • Mylan
  • Pfizer
  • Teva Pharmaceuticals
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Epilepsy and Related Disorders
4.2.2 Rising Geriatric Population with Neuropathic Pain
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.3.2 Availability of Alternatives and Adverse Effects Related to Pregabalin
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Capsules
5.1.2 Oral Solutions
5.1.3 Others
5.2 By Application
5.2.1 Epilepsy
5.2.2 Neuropathic Pain
5.2.3 Anxiety Disorder
5.2.4 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Rest of The World

6.1 Company Profiles
6.1.1 Pfizer
6.1.2 Cipla Limited
6.1.3 Dr. Reddy's Laboratories
6.1.4 MSN Laboratories Ltd
6.1.5 Rising Pharmaceuticals, Inc.
6.1.6 Teva Pharmaceuticals
6.1.7 Sciegen Pharmaceuticals Inc.
6.1.8 Zydus Cadila
6.1.9 Mylan
6.1.10 Medley Pharmaceuticals Limited

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Pfizer
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • MSN Laboratories Ltd
  • Rising Pharmaceuticals, Inc.
  • Teva Pharmaceuticals
  • Sciegen Pharmaceuticals Inc.
  • Zydus Cadila
  • Mylan
  • Medley Pharmaceuticals Limited
Note: Product cover images may vary from those shown